STEPHEN YENZEN LAI to Radiopharmaceuticals
This is a "connection" page, showing publications STEPHEN YENZEN LAI has written about Radiopharmaceuticals.
Connection Strength
0.792
-
[(99m)Tc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial. Ann Surg Oncol. 2015 Oct; 22(11):3708-15.
Score: 0.328
-
Incidental detection of oropharyngeal cancer with fluciclovine PET. Head Neck. 2019 08; 41(8):E141-E145.
Score: 0.110
-
Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. Radiother Oncol. 2017 08; 124(2):248-255.
Score: 0.097
-
Kinetic Modeling and Constrained Reconstruction of Hyperpolarized [1-13C]-Pyruvate Offers Improved Metabolic Imaging of Tumors. Cancer Res. 2015 Nov 15; 75(22):4708-17.
Score: 0.086
-
Sialendoscopy for Patients with Radioiodine-Induced Sialadenitis and Xerostomia. Thyroid. 2015 Jul; 25(7):834-8.
Score: 0.083
-
Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009 Dec 01; 75(5):1493-500.
Score: 0.055
-
Radial spectroscopic MRI of hyperpolarized [1-(13) C] pyruvate at 7 tesla. Magn Reson Med. 2014 Oct; 72(4):986-95.
Score: 0.019
-
Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol. 2010 Nov; 21(11):2278-2283.
Score: 0.015